Pilot Study of Lidocaine 5% Patch Versus Placebo in Patients With Osteoarthritis Pain of the Knee
Overview[ - collapse ][ - ]
| Purpose | Patients with unilateral or bilateral osteoarthritis (OA) of the knee participated in a Phase II clinical trial to assess the efficacy of lidocaine 5% patch compared with placebo in the treatment of pain from OA of the knee. |
|---|---|
| Condition | Osteoarthritis, Knee |
| Intervention | Drug: Lidoderm Drug: Placebo patch |
| Phase | Phase 2 |
| Sponsor | Endo Pharmaceuticals |
| Responsible Party | Endo Pharmaceuticals |
| ClinicalTrials.gov Identifier | NCT00904462 |
| First Received | May 15, 2009 |
| Last Updated | February 9, 2010 |
| Last verified | February 2010 |
Tracking Information[ + expand ][ + ]
| First Received Date | May 15, 2009 |
|---|---|
| Last Updated Date | February 9, 2010 |
| Start Date | August 2004 |
| Estimated Primary Completion Date | Not Provided |
| Current Primary Outcome Measures |
|
| Current Secondary Outcome Measures |
|
Descriptive Information[ + expand ][ + ]
| Brief Title | Pilot Study of Lidocaine 5% Patch Versus Placebo in Patients With Osteoarthritis Pain of the Knee |
|---|---|
| Official Title | A Randomized, Double-Blind, Pilot Study Comparing the Efficacy and Safety of Lidocaine 5% Patch With Placebo in Patients With Pain From Osteoarthritis of the Knee |
| Brief Summary | Patients with unilateral or bilateral osteoarthritis (OA) of the knee participated in a Phase II clinical trial to assess the efficacy of lidocaine 5% patch compared with placebo in the treatment of pain from OA of the knee. |
| Detailed Description | Not Provided |
| Study Type | Interventional |
| Study Phase | Phase 2 |
| Study Design | Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment |
| Condition | Osteoarthritis, Knee |
| Intervention | Drug: Lidoderm Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch. Other Names: Lidocaine 5% patchDrug: Placebo patch Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch. |
| Study Arm (s) |
|
Recruitment Information[ + expand ][ + ]
| Recruitment Status | Completed |
|---|---|
| Estimated Enrollment | 224 |
| Estimated Completion Date | Not Provided |
| Estimated Primary Completion Date | September 2005 |
| Eligibility Criteria | Key Inclusion Criteria: 1. Had unilateral or bilateral OA of the knee diagnosed according to the American College of Rheumatology (ACR) criteria based on clinical and radiographic evidence (presence of osteophytes on x-ray and written evaluation) of OA 2. Had functional capacity class rating of I, II, or III according to ACR classification 3. Had normal 12-lead electrocardiogram (ECG) without any clinically significant abnormalities in heart rate, rhythm, or conduction 4. Had discontinued use of all analgesic medications (including over-the-counter [OTC] analgesics) prior to randomization (patients were allowed limited use of analgesic medications for non study pain 5. At baseline visit, patients were randomized to double-blind treatment if they had an average pain intensity rating for the index joint of 6 or greater (on a 0 to 10 scale) for at least 3 days out of the 5 consecutive days immediately prior to the baseline visit; 0 is defined as "no pain" and 10 is defined as "pain as bad as ever imagined" as measured by Question 5 of the BPI and recorded in a diary 6. At baseline visit, patients were randomized to double-blind treatment if they had, at the baseline visit, an OA severity score for the index joint of 7 or greater on a composite scale of 0 to 24 as measured by the Index of Severity for Osteoarthrosis of the Knee Key Exclusion Criteria: 1. Had been diagnosed with inflammatory arthritis, gout, pseudo-gout or Paget's disease that in the investigator's opinion would have interfered with the assessment of pain and other symptoms of OA 2. Had serious medical conditions requiring daily medications, such as anticonvulsants and tricyclic antidepressants, that could have confounded study results 3. Had any other clinically significant joint disease or prior joint replacement surgery at the index joint 4. Had severe renal insufficiency (creatinine clearance of <30 mL/min) 5. Had moderate or greater hepatic impairment 6. Were taking analgesic medications, glucosamine, or chondroitin that could not be discontinued during the study. Patients taking these medications prior to the study were required to discontinue use for the duration of the study. Patients using opioid analgesics at study entry were required to taper off these medications. 7. Were taking long-acting opioids or opioids that could not be discontinued over the first 5 days of the placebo run-in period. 8. Were using lidocaine-containing product that could not be discontinued during the study 9. Had previously failed treatment with Lidoderm analgesic patch for OA 10. Had recently received either a corticosteroid injection (within 8 weeks) or hyaluronic acid (within 6 months) of study entry 11. Were unable to discontinue use of topical drugs applied to the knee 12. Were taking class I anti-arrhythmic drugs (e.g. mexiletine, tocainide) |
| Gender | Both |
| Ages | 18 Years |
| Accepts Healthy Volunteers | No |
| Contacts | Not Provided |
| Location Countries | United States |
Administrative Information[ + expand ][ + ]
| NCT Number | NCT00904462 |
|---|---|
| Other Study ID Numbers | EN3260-001 |
| Has Data Monitoring Committee | Not Provided |
| Information Provided By | Endo Pharmaceuticals |
| Study Sponsor | Endo Pharmaceuticals |
| Collaborators | Not Provided |
| Investigators | Study Director: Study Director Endo Pharmaceuticals |
| Verification Date | February 2010 |
Locations[ + expand ][ + ]
| United States, Alabama | Birmingham, Alabama, United States |
|---|---|
| United States, Alabama | Hueytown, Alabama, United States |
| United States, Alabama | Tallassee, Alabama, United States |
| United States, Arizona | Phoenix, Arizona, United States |
| United States, Colorado | Boulder, Colorado, United States |
| United States, Florida | Deland, Florida, United States |
| United States, Florida | Largo, Florida, United States |
| United States, Florida | Palm Harbor, Florida, United States |
| United States, Florida | St. Petersburg, Florida, United States |
| United States, Illinois | Chicago, Illinois, United States |
| United States, Illinois | Springfield, Illinois, United States |
| United States, Maryland | Wheaton, Maryland, United States |
| United States, Massachusetts | Peabody, Massachusetts, United States |
| United States, Michigan | Bingham Farms, Michigan, United States |
| United States, Nevada | Reno, Nevada, United States |
| United States, New Jersey | Berlin, New Jersey, United States |
| United States, Ohio | Dayton, Ohio, United States |
| United States, Oklahoma | Oklahoma City, Oklahoma, United States |
| United States, Pennsylvania | Duncansville, Pennsylvania, United States |
| United States, Pennsylvania | Philadelphia, Pennsylvania, United States |
| United States, South Carolina | Charleston, South Carolina, United States |
| United States, Tennessee | Bartlett, Tennessee, United States |
| United States, Tennessee | Cordova, Tennessee, United States |
| United States, Tennessee | Memphis, Tennessee, United States |